Real-world Evaluation of Prevalence of Ocular Adverse Events in Patients With Neovascular (Wet) Agerelated Macular Degeneration (AMD) Who Received Anti-VEGF Agents (IRIS Registry)

Name: Real-world Evaluation of Prevalence of Ocular Adverse Events in Patients With Neovascular (Wet) Agerelated Macular Degeneration (AMD) Who Received Anti-VEGF Agents (IRIS Registry)
Published: 2020
License: Public Domain

Novartis Pharmaceuticals · 2020

ClinicalTrials.gov · Datasets · License: Public Domain · 2020

Open Source ↗

age-related macular degeneration (amd), observational

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Real-world Evaluation of Prevalence of Ocular Adverse Events in Patients With Neovascular (Wet) Agerelated Macular Degeneration (AMD) Who Received Anti-VEGF Agents (IRIS Registry)

Related documents